share_log

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

BioMarin將於太平洋時間5月15日星期三上午10點/美國東部時間下午1點在內華達州拉斯維加斯出席美銀證券2024年醫療保健會議
PR Newswire ·  05/08 08:00

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.

加利福尼亞州聖拉斐爾,2024年5月8日 /PRNewswire/ — BioMarin Pharmaceutical Inc.(納斯達克股票代碼:BMRN)今天宣佈,BioMarin總裁兼首席執行官亞歷山大·哈迪將於太平洋時間2024年5月15日星期三上午10點/美國東部時間下午1點在內華達州拉斯維加斯出席美銀證券2024年醫療保健會議。

An audio webcast of the presentation will be available live. You can access the webcast at: An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

本次演講的網絡音頻直播將直播。您可以通過以下網址訪問網絡直播:會議結束後的有限時間內,還將通過公司網站提供講話的存檔版本。

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit .

關於 BioMarin
BioMarin成立於1997年,是一家全球生物技術公司,致力於通過基因發現改變生活。該公司開發和商業化靶向療法,以解決遺傳病的根本原因。BioMarin無與倫比的研發能力爲罕見遺傳病患者帶來了八種變革性的商業療法。該公司獨特的藥物發現方法已經產生了一系列多樣化的商用、臨床和臨床前候選藥物,這些候選藥物可以滿足未得到滿足的重大醫療需求,具有廣爲人知的生物學,並提供了率先進入市場或與現有治療方案相比提供實質性益處的機會。欲了解更多信息,請訪問。

Contacts:


Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(650) 374-2803

聯繫人:


投資者

媒體

特雷西·麥卡蒂

Marni Kottle

BioMarin 製藥公司

BioMarin 製藥公司

(415) 455-7558

(650) 374-2803

SOURCE BioMarin Pharmaceutical Inc.

來源 BioMarin 製藥公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論